Rueda H A, Scheinberg M A
Clin Rheumatol. 1985 Mar;4(1):68-72. doi: 10.1007/BF02032320.
Previous work at our laboratory has shown that Piroxicam is a potent inhibitor of neutrophil cell migration "in vitro". We have now extended these observations by comparing the effect of Piroxicam "in vivo" on neutrophil and monocyte chemotactic activity as well as comparing the findings with those obtained with Auranofin, a novel oral gold salt preparation. The data presented support the notion that Piroxicam appears to be an inhibitor of neutrophil cell function while Auranofin predominantly affects monocyte cell migration.